Clinical trials: Chronic Hepatitis B Infections
Hepatitis B
Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients
The purpose of this study is to find out if a new investigational hepatitis B virus vaccine, HEPLISAV™, is safe in patients at least 40 years of age who have progressive loss of kidney function with more advanced stage 3 (GFR ≤…
- Trial name
- NCT00426712
- Testing
- 1018 ISS immunostimulatory oligonucleotide with HBV surface antigen, Hepatitis B Vaccine (Recombinant)
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- Dynavax Technologies Corporation
Hepatitis B, Chronic, Pregnancy Related
Maternal Therapy With TAF Versus TDF to Prevent Vertical Transmission of Hepatitis B
Immunoprophylaxis failure of hepatitis B (HBV) remains a concern and has been reported in approximately 10-30% of infants born to highly viremic mothers with HBeAg-positive.
- Trial name
- NCT04211805
- Testing
- Tenofovir Alafenamide 25 MG for arm (A), Tenofovir Disoproxil Fumarate 300mg for arm (B)
- Where
- 11 sites in China
- Volunteers
- 450 people
- Sponsor
- New Discovery LLC
Hepatitis C
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Substudy C: The purpose of this substudy is to determine whether Lambda combined with Ribavirin and Daclatasvir for 12 weeks is efficacious in treatment naïve subjects with genotype 1b chronic HCV infection
- Trial name
- D-LITE (NCT01795911)
- Testing
- Pegylated Interferon Lambda, Ribasphere, Daclatasvir
- Where
- United States
- Volunteers
- 165 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis B, Chronic
A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B.
This randomized, 2 x 2 factorial, parrallel group study will compare the efficacy and safety of 48 versus 96 weeks of peginterferon alfa-2a [Pegasys], with or without entecavir, in patients with HbeAg negative chronic hepatitis…
- Trial name
- NCT01179594
- Testing
- entecavir, peginterferon alfa-2a [Pegasys]
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis B, Acute Hepatitis B
Disease Loads and Status of Treatment
The aim of study is to evaluate the current prevalence of HDV infection, and comprehensively analyze the interaction between HDV and HBV infections in the era of NAs in Taiwan.
- Conditions
- Chronic Hepatitis B, Acute Hepatitis B, Hepatitis D
- Trial name
- NCT05264272
- Testing
- Prospective serological assays, Retrospective serological assays
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Liver Cirrhosis, Chronic Hepatitis B
Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB)
Antiviral treatment on Chronic Hepatitis B (CHB) patients with liver cirrhosis is compulsory and effective. Telbivudine, which is superior to lamivudine in the treatment of CHB,is considered to be appropriate for the antiviral…
- Trial name
- NCT01380951
- Testing
- telbivudine
- Where
- China
- Volunteers
- 120 people
- Sponsor
- The Fifth People's Hospital of Suzhou
Chronic Hepatitis B
Effects of Telbivudine and Tenofovir Disproxil Fumarate on the Kinetics of Hepatitis B Virus DNA in Chronic Hepatitis B (CHB)
The purpose of this study is to compare the safety, tolerability and effectiveness of 12 weeks of treatment with telbivudine 600 mg daily plus tenofovir DF 300 mg once daily (QD) taken together versus tenofovir DF 300 mg once…
- Trial name
- NCT00804622
- Testing
- telbivudine, tenofovir disproxil fumarate, telbivudine plus tenofovir disproxil fumarate
- Where
- China
- Volunteers
- 15 people
- Sponsor
- The University of Hong Kong
Acute on Chronic Liver Failure, Hepatitis B
Randomized Controlled Trial of Tenofovir in Patients of Reactivation of Hepatitis B Presenting as Acute on Chronic Liver Failure
Background: Reactivation of hepatitis B is a well-characterized syndrome marked by the abrupt reappearance or rise of hepatitis B virus (HBV) DNA in the serum of a patient with previously inactive or resolved HBV infection.
- Trial name
- ACLF (NCT01074645)
- Testing
- Tenofovir disoproxil fumarate (TDF)
- Where
- India
- Volunteers
- 27 people
- Sponsor
- Govind Ballabh Pant Hospital
Hepatitis B, Chronic
Efficacy and Safety of Switching to Vemliver From Entecavir in Chronic Hepatitis B Patients Previously Treated With Entecavir
Enroll patients who are pre-treated with Entecavir at least 24 weeks and confirmed HBV antiviral (HBV DNA <69 IU/mL) effects. Subjects are given one test drug or comparator once a day for 48 weeks according to the results of…
- Trial name
- NCT06000657
- Testing
- Vemliver tablet, Baracross Tablet
- Where
- South Korea
- Volunteers
- 196 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
HBV Related Acute-on-chronic Liver Failure, HBV-related Liver Cirrhosis
Analysis of Methylomic Features and Prognostic Risk Prediction in Patients With Hepatitis B-related Acute-on-chronic Liver Failure
This study aims to investigate the methylomic features of patients with hepatitis B-related acute-on-chronic liver failure and establish and validate a prognostic risk prediction classification model.
- Conditions
- HBV Related Acute-on-chronic Liver Failure, HBV-related Liver Cirrhosis, HBV (Hepatitis B Virus)
- Trial name
- NCT07275554
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Qilu Hospital of Shandong University
Hepatitis B, Chronic
A Clinical Research on Disease Progression and Intervention of Chronic HepatitisB
HBV(hepatitis B virus) with metabolic comorbidities may accelerate liver disease progression and increase the risk of HCC(Hepatocellular Carcinoma)development.
- Trial name
- NCT05057065
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Hong Ren
Chronic Hepatitis B
Different Regimens of Pegylated Interferon and Lamivudine Combination Therapy in Chronic Hepatitis B Patients
The aim is to investigate the best treatment regime of PEG-Intron A and lamivudine combination in terms of viral clearance in chronic hepatitis B patients.
- Trial name
- NCT00226447
- Testing
- Pegylated Interferon, Lamivudine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese University of Hong Kong
Hepatitis B, HBV
Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor
An open-label, Phase 2, exploratory study to examine the safety and efficacy of inarigivir in non-cirrhotic, hepatitis B e antigen (HBeAg)-negative subjects with chronic HBV infection.
- Conditions
- Hepatitis B, HBV, Hepatitis B, Chronic
- Trial name
- NCT04023721
- Testing
- Inarigivir soproxil, Nucleoside/nucleotide (NUC) analogue inhibitors
- Where
- 7 sites in Canada, United Kingdom
- Volunteers
- 64 people
- Sponsor
- F-star Therapeutics, Inc.
Human Immunodeficiency Virus, Hepatitis B, Chronic
Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions
The purpose of this study is to compare the liver toxicity in HIV-infected patients with chronic hepatitis B and/or hepatitis C, who start a new antiretroviral drug regimen, as well as the influence of the degree of pre-existing…
- Conditions
- Human Immunodeficiency Virus, Hepatitis B, Chronic, Hepatitis C, Chronic
- Trial name
- NCT01908660
- Testing
- antiretroviral drugs
- Where
- Spain
- Volunteers
- 192 people
- Sponsor
- Valme University Hospital
Hepatitis Delta With Hepatitis B Carrier State, Chronic Hepatitis b
Hepatitis Delta Virus Infection: Cross-sectional Study in Patients With Chronic Hepatitis B Virus Infection
The goal of this observational study is to determine the prevalence of hepatitis D virus (HDV) and the distribution of the HDV genotype in patients with chronic hepatitis B infection.
- Trial name
- NCT06638320
- Where
- 3 sites in Vietnam
- Volunteers
- 2,452 people
- Sponsor
- Tam Anh Research Institute
Fatty Liver, Chronic Hepatitis b
Steatohepatitis in Chronic Hepatitis B
Fatty liver disease is increasingly recognized in patients with chronic hepatitis B (CHB). Whether concurrent fatty liver disease affects the long-term outcomes of CHB is unclear.
- Trial name
- NCT05317260
- Testing
- Antiviral Agents
- Where
- Thailand
- Volunteers
- 408 people
- Sponsor
- Mahidol University
Hepatitis B
Study of Sequential GSK3228836 and Peginterferon Treatment in Participants With Chronic Hepatitis B (CHB)
This study is intended to evaluate if 12 or 24 weeks of treatment with GSK3228836 followed by up to 24 weeks of pegylated interferon (PegIFN) can increase the rate of hepatitis B virus surface antigen (HBsAg) loss in participants…
- Trial name
- B-Together (NCT04676724)
- Testing
- GSK3228836, PegIFN, NA therapy
- Where
- 49 sites in United States, Canada and 9 more
- Volunteers
- 108 people
- Sponsor
- GlaxoSmithKline
Hepatitis B, Chronic
An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants
The purpose of this study is to evaluate efficacy of the study intervention, based on hepatitis B surface antigen (HBsAg) levels at follow-up (FU) Week 24.
- Trial name
- OCTOPUS-1 (NCT05275023)
- Testing
- JNJ-73763989, PD-1 inhibitor, Tenofovir Disoproxil
- Where
- 26 sites in Canada, Czechia and 6 more
- Volunteers
- 37 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Hepatitis
Hepatic Steatosis and Chronic Hepatitis B Virus
This study aims to evaluate the prevalence and severity of hepatic steatosis in CHB and investigate the relationship between hepatic steatosis and viral load, liver biochemistry, liver fibrosis, and inflammation in CHB
- Trial name
- NCT05678582
- Testing
- Liver biopsy
- Where
- Egypt
- Volunteers
- 91 people
- Sponsor
- Sohag University
Chronic Hepatitis B
Tenofovir Disoproxil Fumarate vs. Entecavir in Chronic Hepatitis B Patients With Partial Virologic Response to Entecavir
Entecavir, a potent antiviral agent, has been widely used for treatment-naïve chronic hepatitis B patients. However, about 20% of patients showed partial virologic response after 2 year of entecavir therapy (33% in HBeAg…
- Trial name
- STEEP (NCT01711567)
- Testing
- tenofovir, entecavir
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Korea University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.